As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of CRISPR Therapeutics AG. The largest reported stake is ARK Investment Management LLC's, at 11.79%. 10 filings are on record since July 17, 2025 (Schedule 13G/A, April 30, 2026).
Sell to companies like CRISPR Therapeutics AG? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Orbis Investment Management Ltd · Sole voting: 5,433,344 · Shared voting: 0 · Sole dispositive: 5,433,344 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: BlackRock, Inc. · Sole voting: 7,841,979 · Shared voting: 0 · Sole dispositive: 7,987,262 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-27
- · Holder: Orbis Investment Management Ltd · Percent: 6.3% · SCHEDULE 13G/A
- · Reporting person: Capital World Investors · Sole voting: 4,897,705 · Shared voting: 0 · Sole dispositive: 4,929,428 · Shared dispositive: 0 · SCHEDULE 13G, 2026-05-14
- · Holder: ARK Investment Management LLC · Percent: 11.79% · SCHEDULE 13G/A
CRISPR Therapeutics AG has 10 Schedule 13D or 13G filings on record since 2025-07-17. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| ARK Investment Management LLC | 11.79% | 11,313,623 | SCHEDULE 13G/A, 2026-04-30 | 2026-03-31 |
| BlackRock, Inc. | 8.3% | 7,987,262 | SCHEDULE 13G/A, 2026-07-27 | 2026-06-30 |
| Orbis Investment Management Ltd | 5.6% | 5,433,344 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Capital World Investors | 5.1% | 4,929,428 | SCHEDULE 13G, 2026-05-14 | 2026-03-31 |
| Capital International Investors | 1.2% | 1,186,794 | SCHEDULE 13G/A, 2026-02-05 | 2026-01-30 |
Holding shares or following this stake? See who's behind CRISPR Therapeutics AG and the warning signs.
Free to see. No signup.
Keep reading
More on CRISPR Therapeutics AG and the records around it.
CRISPR Therapeutics AG elsewhere on the record
Companies that share a holder
- ARK Investment Management LLC also filed stake reports on 20 other companies: Tempus AI, Inc. (Nov 2026), 10x Genomics, Inc. (Oct 2026), Twist Bioscience Corp (Sep 2026)
- ORBIS INVESTMENT MANAGEMENT LTD also filed stake reports on 23 other companies: RXO, Inc. (Nov 2026), National CineMedia, Inc. (Sep 2026), BBB FOODS INC (Aug 2026)
- Capital International Investors also filed stake reports on 96 other companies: Aurora Innovation, Inc. (Nov 2026), Arxis, Inc. (Aug 2026), Astronics Corp. (Aug 2026)
Watch CRISPR Therapeutics AG
Get an email when CRISPR Therapeutics AG files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on CRISPR Therapeutics AG?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on CRISPR Therapeutics AG: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CRISPR Therapeutics AG covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7,841,979 | 0 | 7,987,262 | 0 | SCHEDULE 13G/A, 2026-07-27 |
| Orbis Investment Management Ltd | 5,433,344 | 0 | 5,433,344 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Allan Gray Australia Pty Ltd | 15,817 | 0 | 15,817 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Capital World Investors | 4,897,705 | 0 | 4,929,428 | 0 | SCHEDULE 13G, 2026-05-14 |
The latest filing identifies CRISPR Therapeutics AG by CUSIP H17182108 and gives its principal executive office as BAARERSTRASSE 14, ZUG (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | BlackRock, Inc. | 6.9% | SCHEDULE 13G |
| 2025-11-04 | ARK Investment Management LLC | 10.76% | SCHEDULE 13G/A |
| 2025-11-14 | Orbis Investment Management Ltd | 5.5% | SCHEDULE 13G |
| 2026-02-05 | Capital International Investors | 1.2% | SCHEDULE 13G/A |
| 2026-02-17 | Orbis Investment Management Ltd | 6.2% | SCHEDULE 13G/A |
| 2026-04-30 | ARK Investment Management LLC | 11.79% | SCHEDULE 13G/A |
| 2026-05-14 | Capital World Investors | 5.1% | SCHEDULE 13G |
| 2026-05-15 | Orbis Investment Management Ltd | 6.3% | SCHEDULE 13G/A |
| 2026-07-27 | BlackRock, Inc. | 8.3% | SCHEDULE 13G/A |
| 2026-08-14 | Orbis Investment Management Ltd | 5.6% | SCHEDULE 13G/A |
Questions about who owns CRISPR Therapeutics AG
Who owns CRISPR Therapeutics AG?
On this page, 4 holders' latest ownership filings report 5% or more of CRISPR Therapeutics AG: ARK Investment Management LLC (11.79%, Schedule 13G/A, filed 2026-04-30), BlackRock, Inc. (8.3%, Schedule 13G/A, filed 2026-07-27), Orbis Investment Management Ltd (5.6%, Schedule 13G/A, filed 2026-08-14) and Capital World Investors (5.1%, Schedule 13G, filed 2026-05-14).
Who are the largest shareholders of CRISPR Therapeutics AG?
By the share each holder's latest filing reports, the largest holders of CRISPR Therapeutics AG on this page are ARK Investment Management LLC (11.79%), BlackRock, Inc. (8.3%) and Orbis Investment Management Ltd (5.6%).
When did ARK Investment Management LLC buy into CRISPR Therapeutics AG?
The filings give report dates, not purchase dates. The earliest filing from ARK Investment Management LLC on this page is the Schedule 13G/A, filed 2025-11-04, reporting 10.76%; its latest, Schedule 13G/A filed 2026-04-30, reports 11.79%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for CRISPR Therapeutics AG
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 19, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for CRISPR Therapeutics AG. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.